Best in Biotech 22 Aug 2024
Seven companies transforming the biotech industry in Italy
Delve into Italy’s biotech landscape with seven companies that are leading the charge in the European country.
About
After I graduated with a master’s degree in European Law from the
University of Tours, I decided to study journalism at the All Media
Journalism Institute of Lille. During this time, I discovered the healthcare
innovation ecosystem and enjoyed writing about it for Eurasanté, a French
healthcare cluster. I am interested in different subjects other than
healthcare and biotechnology: cinema, sports, photography… Journalism
had always been at the back of my mind, and I am delighted to write for
Labiotech as a junior reporter. When I am not working you might find me on the tennis court or picking up the next piece of furniture I will renovate.
Articles by Jules Adam
In Depth 1 Aug 2024
CureVac: From a failed drug to a €1.45 billion deal
In 2021, CureVac’s COVID-19 candidate came short. Discover how the company leveraged its deal with GSK to restructure and turn things around.
News and Trends 29 Jul 2024
Influenza solution deals pile up as pandemic preparedness increases
Influenza deals have been piling up in the last few weeks. Discover why that is and how are companies and government preparing for pandemics.
More News! 26 Jul 2024
Confo Therapeutics raises $60 million to focus on agonistic GPCR antibodies
Discover the field of agonistic GPCR antibodies after Confo therapeutics successfully raised $60 million in its series B round.
More News! 23 Jul 2024
First AKT-targeting drug capivasertib to hit the market, could it open the door for more?
As AstraZeneca and Astex’s capivasertib gains market presence in breast cancer, could it be the time for AKT inhibitors? Let’s find out!
More News! 17 Jul 2024
Is tau protein the key to defeating Alzheimer’s? Asceneuron thinks so and raises $100 million to prove it
Discover yet another exciting deal in biotech with Asceneuron raising $100 million to advance its Alzheimer’s candidate, ASN51.
ADVERTISEMENT
ADVERTISEMENT
News and Trends 16 Jul 2024
German biotech raises $150M on its way to tackle cancer therapy resistance
On its way to tackle cancer therapy resistance with its monoclonal antibody visugromab, CataLym completes a $150 million series D round.
Best in Biotech 12 Jul 2024
Five universities in Canada to build a career in biotech in 2024
Delve into Canada’s biotech education ecosystem with five universities putting industry experience forward.
More News! 11 Jul 2024
CDMO trends post-Wuxi’s exit from the US: who will take its place?
The BIOSECURE Act is reshuffling the deck and Indian CDMOs are looking good. Discover the trends in this evolving landscape.
Expert Advice 5 Jul 2024
The ABC of biotech startup funding
Funding a biotech startup can be challenging. Delve into our guide to navigate this complicated investment landscape.
Best in Biotech 2 Jul 2024
Swiss biotech going strong in 2024: 18 companies to put on your radar
Switzerland is a booming biotech hotspot in Europe boasting many high-profile companies. Here are 18 promising Swiss biotech companies.
Podcast 28 Jun 2024
Priovant – finding treatments for autoimmune diseases
Listen to our conversation with Priovant Therapeutics, developing therapies for autoimmune diseases with high morbidity.
ADVERTISEMENT
